Advertisement

Pediatric Nephrology

, Volume 30, Issue 5, pp 775–781 | Cite as

Eculizumab hepatotoxicity in pediatric aHUS

  • Wesley Hayes
  • Sibylle Tschumi
  • Simon C. Ling
  • Janusz Feber
  • Michael Kirschfink
  • Christoph LichtEmail author
Original Article

Abstract

Background

Eculizumab is a humanized anti-C5 antibody approved for the treatment of atypical hemolytic uremic syndrome (aHUS). Its use is increasing in children following reports of its safety and efficacy.

Methods

We reviewed biochemical and clinical data related to possible drug-induced liver injury in 11 children treated with eculizumab for aHUS in a single center.

Results

Elevated aminotransferases were observed in 7 children aged 6 to 11 years following eculizumab treatment for aHUS. Internationally accepted liver enzyme thresholds for drug-induced liver injury were exceeded in 5 cases. In all cases, liver injury was classified as mixed hepatocellular and cholestatic. Infectious and other causes were excluded in each case. One patient with no pre-existing liver disease developed tender hepatomegaly and liver enzyme derangement exceeding 20 times the upper limit of normal following initiation of eculizumab. Recurrent liver injury following re-challenge with eculizumab necessitated its discontinuation and transition to plasma therapy.

Conclusions

Hepatotoxicity in association with eculizumab is a potentially important yet previously unreported adverse event. We recommend monitoring liver enzymes in all patients receiving eculizumab. Further research is required to clarify the impact of this adverse event, to characterize the mechanism of potential hepatotoxicity, and to identify which patients are most at risk.

Keywords

Atypical hemolytic uremic syndrome Thrombotic microangiopathy Complement Eculizumab Transaminitis Hepatotoxicity 

Notes

Acknowledgements

The authors wish to thank Camille Bedrosian, MD, CMO, Alexion Pharmaceuticals, for helpful discussion of this manuscript.

Disclosures

CL is advisory board member of Alexion Pharmaceuticals and Achillon Pharmaceuticals. He has received travel and speaker stipends as well as unrestricted research funds from Alexion Pharmaceuticals.

Conflict of interest

The other authors declare no conflict of interest.

References

  1. 1.
    Hillmen P, Hall C, Marsh JC, Elebute M, Bombara MP, Petro BE, Cullen MJ, Richards SJ, Rollins SA, Mojcik CF, Rother RP (2004) Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 350:552–559CrossRefPubMedGoogle Scholar
  2. 2.
    Brodsky RA, Young NS, Antonioli E, Risitano AM, Schrezenmeier H, Schubert J, Gaya A, Coyle L, de Castro C, Fu CL, Maciejewski JP, Bessler M, Kroon HA, Rother RP, Hillmen P (2008) Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 111:1840–1847CrossRefPubMedGoogle Scholar
  3. 3.
    Hillmen P, Young NS, Schubert J, Brodsky RA, Socie G, Muus P, Roth A, Szer J, Elebute MO, Nakamura R, Browne P, Risitano AM, Hill A, Schrezenmeier H, Fu CL, Maciejewski J, Rollins SA, Mojcik CF, Rother RP, Luzzatto L (2006) The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 355:1233–1243CrossRefPubMedGoogle Scholar
  4. 4.
    Schmidtko J, Peine S, El-Housseini Y, Pascual M, Meier P (2013) Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab. Am J Kidney Dis 61:289–299CrossRefPubMedGoogle Scholar
  5. 5.
    Hodgkins KS, Bobrowski AE, Lane JC, Langman CB (2012) Clinical grand rounds: atypical hemolytic uremic syndrome. Am J Nephrol 35:394–400CrossRefPubMedGoogle Scholar
  6. 6.
    Gruppo RA, Rother RP (2009) Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med 360:544–546CrossRefPubMedGoogle Scholar
  7. 7.
    Nurnberger J, Philipp T, Witzke O, Opazo Saez A, Vester U, Baba HA, Kribben A, Zimmerhackl LB, Janecke AR, Nagel M, Kirschfink M (2009) Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 360:542–544CrossRefPubMedGoogle Scholar
  8. 8.
    Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nurnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368:2169–2181CrossRefPubMedGoogle Scholar
  9. 9.
    Gleesing J, Chiwane S, Rongkavilit C (2012) Gonococcal septic shock associated with eculizumab treatment. Pediatr Infect Dis J 31:543CrossRefPubMedGoogle Scholar
  10. 10.
    Balagula Y, Newman SB, Lacouture ME (2010) Photodermatosis associated with eculizumab (Soliris): a novel monoclonal antibody directed against the complement protein C5. Am J Hematol 85:392–393PubMedGoogle Scholar
  11. 11.
    Manganoni AM, Pavoni L, Facchetti F, Farisoglio C, Sereni E, Calzavara-Pinton P (2012) Melanoma in a patient in treatment with eculizumab. Ann Hematol 91:135–136CrossRefPubMedGoogle Scholar
  12. 12.
    Knoll BM, Letendre L, Steensma DP (2008) Life-threatening desquamating rash and hyperammonemia following administration of eculizumab for paroxysmal nocturnal hemoglobinuria. Am J Hematol 83:881–883CrossRefPubMedGoogle Scholar
  13. 13.
    Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, Hunt CM, Wilke RA, Avigan M, Kaplowitz N, Bjornsson E, Daly AK (2011) Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 89:806–815CrossRefPubMedGoogle Scholar
  14. 14.
    Unizony S, Arias-Urdaneta L, Miloslavsky E, Arvikar S, Khosroshahi A, Keroack B, Stone JR, Stone JH (2012) Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res 64:1720–1729CrossRefGoogle Scholar
  15. 15.
    Navarro-Millan I, Singh JA, Curtis JR (2012) Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. Clin Ther 34:788–802CrossRefPubMedCentralPubMedGoogle Scholar
  16. 16.
    Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ, Schweizer C, Weil S, Laheru D (2010) Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res 16:6132–6138CrossRefPubMedCentralPubMedGoogle Scholar
  17. 17.
    Langenberg MH, Witteveen PO, Lankheet NA, Roodhart JM, Rosing H, van den Heuvel IJ, Beijnen JH, Voest EE (2010) Phase 1 study of combination treatment with PTK 787/ZK 222584 and cetuximab for patients with advanced solid tumors: safety, pharmacokinetics, pharmacodynamics analysis. Neoplasia 12:206–213PubMedCentralPubMedGoogle Scholar
  18. 18.
    Trarbach T, Moehler M, Heinemann V, Kohne CH, Przyborek M, Schulz C, Sneller V, Gallant G, Kanzler S (2010) Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. Br J Cancer 102:506–512CrossRefPubMedCentralPubMedGoogle Scholar
  19. 19.
    Ierardi E, Valle ND, Nacchiero MC, De Francesco V, Stoppino G, Panella C (2006) Onset of liver damage after a single administration of infliximab in a patient with refractory ulcerative colitis. Clin Drug Invest 26:673–676CrossRefGoogle Scholar
  20. 20.
    Menghini VV, Arora AS (2001) Infliximab-associated reversible cholestatic liver disease. Mayo Clin Proc 76:84–86CrossRefPubMedGoogle Scholar
  21. 21.
    Saleem G, Li SC, MacPherson BR, Cooper SM (2001) Hepatitis with interface inflammation and IgG, IgM, and IgA anti-double-stranded DNA antibodies following infliximab therapy: comment on the article by Charles et al. Arthritis Rheum 44:1966–1968CrossRefPubMedGoogle Scholar
  22. 22.
    Germano V, Picchianti Diamanti A, Baccano G, Natale E, Onetti Muda A, Priori R, Valesini G (2005) Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis 64:1519–1520CrossRefPubMedCentralPubMedGoogle Scholar
  23. 23.
    Tobon GJ, Canas C, Jaller JJ, Restrepo JC, Anaya JM (2007) Serious liver disease induced by infliximab. Clin Rheumatol 26:578–581CrossRefPubMedGoogle Scholar
  24. 24.
    Soto-Fernandez S, Gonzalez-Carro P, De Pedro-Esteban A, Legaz-Huidobro ML, Perez-Roldan F, Roncero Garcia-Escribano O, Valbuena-Gonzalez M, Ruiz-Carrillo F (2006) Infliximab-induced hepatitis in a patient with Crohn’s disease. Gastroenterol Hepatol 29:321–322CrossRefPubMedGoogle Scholar
  25. 25.
    Ozorio G, McGarity B, Bak H, Jordan AS, Lau H, Marshall C (2007) Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis. Med J Aust 187:524–526PubMedGoogle Scholar
  26. 26.
    Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L (2007) Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 25:1256–1264CrossRefPubMedGoogle Scholar
  27. 27.
    Brodsky A, Mazzocchi O, Sanchez F, Khursigara G, Malhotra S, Volpacchio M (2012) Eculizumab in paroxysmal nocturnal hemoglobinuria with Budd-Chiari syndrome progressing despite anticoagulation. Exp Hematol Oncol 1:26CrossRefPubMedCentralPubMedGoogle Scholar
  28. 28.
    Dragon-Durey MA, Sethi SK, Bagga A, Blanc C, Blouin J, Ranchin B, Andre JL, Takagi N, Cheong HI, Hari P, Le Quintrec M, Niaudet P, Loirat C, Fridman WH, Fremeaux-Bacchi V (2010) Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol 21:2180–2187CrossRefPubMedCentralPubMedGoogle Scholar
  29. 29.
    Loriot Y, Perlemuter G, Malka D, Penault-Llorca F, Boige V, Deutsch E, Massard C, Armand JP, Soria JC (2008) Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat Clin Pract Oncol 5:268–278CrossRefPubMedGoogle Scholar
  30. 30.
    McKoy JM, Angelotta C, Bennett CL, Tallman MS, Wadleigh M, Evens AM, Kuzel TM, Trifilio SM, Raisch DW, Kell J, DeAngelo DJ, Giles FJ (2007) Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res 31:599–604CrossRefPubMedGoogle Scholar
  31. 31.
    Maniecki MB, Hasle H, Friis-Hansen L, Lausen B, Nielsen OJ, Bendix K, Moestrup SK, Moller HJ (2008) Impaired CD163-mediated hemoglobin-scavenging and severe toxic symptoms in patients treated with gemtuzumab ozogamicin. Blood 112:1510–1514CrossRefPubMedGoogle Scholar
  32. 32.
    Mastellos D, Papadimitriou JC, Franchini S, Tsonis PA, Lambris JD (2001) A novel role of complement: mice deficient in the fifth component of complement (C5) exhibit impaired liver regeneration. J Immunol 166:2479–2486CrossRefPubMedGoogle Scholar
  33. 33.
    Schieferdecker HL, Schlaf G, Jungermann K, Gotze O (2001) Functions of anaphylatoxin C5a in rat liver: direct and indirect actions on nonparenchymal and parenchymal cells. Int Immunopharmacol 1:469–481CrossRefPubMedGoogle Scholar
  34. 34.
    Cao Y, Marks JD, Huang Q, Rudnick SI, Xiong C, Hittelman WN, Wen X, Marks JW, Cheung LH, Boland K, Li C, Adams GP, Rosenblum MG (2012) Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity. Mol Cancer Ther 11:143–153CrossRefPubMedGoogle Scholar
  35. 35.
    Herlitz LC, Bomback AS, Markowitz GS, Stokes MB, Smith RN, Colvin RB, Appel GB, D’Agati VD (2012) Pathology after eculizumab in dense deposit disease and C3 GN. J Am Soc Nephrol 23:1229–1237CrossRefPubMedCentralPubMedGoogle Scholar
  36. 36.
    Hillebrandt S, Wasmuth HE, Weiskirchen R, Hellerbrand C, Keppeler H, Werth A, Schirin-Sokhan R, Wilkens G, Geier A, Lorenzen J, Kohl J, Gressner AM, Matern S, Lammert F (2005) Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. Nat Genet 37:835–843CrossRefPubMedGoogle Scholar
  37. 37.
    Andrade RJ, Lucena MI, Kaplowitz N, Garcia-Munoz B, Borraz Y, Pachkoria K, Garcia-Cortes M, Fernandez MC, Pelaez G, Rodrigo L, Duran JA, Costa J, Planas R, Barriocanal A, Guarner C, Romero-Gomez M, Munoz-Yague T, Salmeron J, Hidalgo R (2006) Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. Hepatology 44:1581–1588CrossRefPubMedGoogle Scholar

Copyright information

© IPNA 2014

Authors and Affiliations

  • Wesley Hayes
    • 1
  • Sibylle Tschumi
    • 1
  • Simon C. Ling
    • 2
    • 3
  • Janusz Feber
    • 4
  • Michael Kirschfink
    • 5
  • Christoph Licht
    • 1
    • 3
    Email author
  1. 1.Division of NephrologyThe Hospital for Sick ChildrenTorontoCanada
  2. 2.Division of Gastroenterology, Hepatology and NutritionThe Hospital for Sick ChildrenTorontoCanada
  3. 3.Department of PaediatricsUniversity of TorontoTorontoCanada
  4. 4.Division of NephrologyChildren’s Hospital of Eastern OntarioOttawaCanada
  5. 5.Division of ImmunologyUniversity of HeidelbergHeidelbergGermany

Personalised recommendations